Abstract:Objective:To discuss ethical review and management of serious adverse events in anti-tumor drug clinical trials in a grade A tertiary cancer hospital for timely and effective protection of subjects.Methods:The main contents and ethical management of ethical review on serious adverse events were retrospectively analyzed including the number, distribution rules, and whether they were reported in time in clinical trials conducted in our hospital in 2021.Results:A total of 1 789 serious adverse events in 259 clinical trials were reported, with more male subjects than female, with an average age of 59.95 years, mainly concentrated in the 50~59 age and 60~69 age groups, accounting for 27.45% and 42.37% respectively. Digestive oncology department, thoracic oncology department and renal cancer melanoma department ranked in the top three for the number of clinical trials and reports of serious adverse events. The highest incidence of serious adverse events was hospitalization at 63.44% and the lowest incidence was disability at 0.39%. The highest proportion of serious adverse events possibly related to clinical trials was 35.72%. Expected serious adverse events accounted for 65.85% versus 34.15% unexpected ones, and the difference between different correlations of serious adverse events whether they were expected or not.was statistically significant. Among the measures taken by the investigator for the test drugs due to serious adverse events, drug discontinuation was the most, accounting for 42.54%, while 3.07% of the trial plans modified the study protocol/informed consent. Serious adverse events reported within 24 hours accounted for 87.20%, and those reported in 24 hours and beyond accounting for 12.80%. A statistically significant difference of the reporting time between the registered and investigator initiated clinical trials was observed.Conclusions:The ethics committee should attach importance to ethical review and management of serious adverse events, pay attention to whether they were reported timely and accurately, strengthen supervision, and effectively protect the safety and interests of the subjects.

Retrospective analysis on protocol violation of anti-tumor drug clinical trials from the perspective of ethical review

Analysis and management of non-compliance/protocol violation or deviation during clinical trials

Ethical review and management of serious adverse events in anti-tumor drug clinical trials

Protocol Deviations in Clinical Trials of New Drug Application

Protection of Human Rights in Clinical Trials

Discussion on the construction of management system for clinical trial investigators

Analysis and discussion on the subject complaint in clinical drug trials

Ethics Committee' s Management of Noncompliance/Violation or Protocol Deviation Report in Clinical Research

Common Problems in the Ethical Review of Clinical Trial Protocols and the Countermeasures

Analysis of warning letters issued to investigators by United States Food and Drug Administration

Survey and analysis of insurance for volunteers in clinical trials of new drugs and medical instruments

Effect of Evidence-Based Nursing Management of Protocol Compliance in Anticancer Drug Clinical Trial

Investigation of Problems in Clinical Drug Trials in the Past 5 years

Study on the Design of Clinical Trial Protocol for New Drugs

Rethinking the clinical research protocol: Lessons learned from the COVID-19 pandemic and recommendations for reducing noncompliance

How the clinical research community responded to the COVID-19 pandemic: An analysis of the COVID-19 clinical studies in ClinicalTrials.gov

Comparison of Primary Endpoints Between Publications, Registries, and Protocols of Phase III Cancer Clinical Trials

Cause analysis and control measures of common problems in clinical part from drug clinical trial data inspection

Study on the Standardization of Initial Ethical Review of Drug Clinical Trial

Supplementary Table S3 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation

Analysis of Suspension of Clinical Trials for Drug Registration in China